Magnesium compositions and uses thereof for cancers
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9937137-B2
Publication Date
2018-04-10
Expiration Date
Abstract
Compositions and methods that are useful for treating a subject suffering from one or more cancers are provided herein. Such compositions and methods can contain an effective amount of magnesium threonate to be used to support or improve the mental state of a subject. The composition and methods comprising magnesium threonate can also be used to support a cancer treatment.
Core Innovation
The problem is to treat a solid or cystic tumor in a subject in need thereof. The disclosed approach administers a pharmaceutical composition comprising an effective amount of magnesium threonate to thereby treat the solid or cystic tumor. The solid or cystic tumor is a cancer selected from the group consisting of breast cancer, lung cancer, prostate cancer, gastric cancer, head & neck cancer, melanoma, bladder cancer, neuroendocrine cancer, squamous carcinoma, cervical cancer, vulvar cancer, thyroid cancer, pancreatic cancer, renal cancer, esophageal cancer, rectal cancer, penile cancer, multiple myeloma, Merkel cell tumors, ovarian cancer and colorectal cancer.
The disclosure further frames treatment in terms of achieving physiological magnesium concentration in serum, plasma, or cerebrospinal fluid. The method includes administering an effective amount of magnesium threonate such that the physiological magnesium concentration is 0.75 mM or above. In some embodiments, the effective amount increases the physiological magnesium concentration by at least 10% versus the initial magnesium level prior to administration.
The disclosed magnesium threonate compositions and administration are described as pharmaceutical compositions, including formulations contained within a foodstuff and oral administration in some embodiments. The disclosure also indicates that an additional cancer therapeutic can be provided in conjunction with magnesium threonate, and that treatment duration can be extended, including durations of at least about 1 week or 1 month.
Claims Coverage
The independent claim is directed to treating a solid or cystic tumor by administering an effective amount of magnesium threonate. The dependent claims refine the method by specifying magnesium concentration/exposure requirements, dosage limits, optional combination with an additional cancer therapeutic, and example formulation/administration forms.
Magnesium threonate treatment of solid or cystic tumors
Administering to the subject a pharmaceutical composition comprising an effective amount of magnesium threonate thereby treating a solid or cystic tumor in the subject, where the tumor is a cancer selected from the group consisting of breast cancer, lung cancer, prostate cancer, gastric cancer, head & neck cancer, melanoma, bladder cancer, neuroendocrine cancer, squamous carcinoma, cervical cancer, vulvar cancer, thyroid cancer, pancreatic cancer, renal cancer, esophageal cancer, rectal cancer, penile cancer, multiple myeloma, Merkel cell tumors, ovarian cancer and colorectal cancer.
Physiological magnesium concentration threshold in serum, plasma, or cerebrospinal fluid
Administering an effective amount of magnesium such that a physiological magnesium concentration is 0.75 mM or above in serum, plasma, or cerebrospinal fluid.
At least 10% increase versus initial physiological magnesium level
Administering an effective amount that increases a subject’s physiological magnesium concentration by at least 10% versus the initial magnesium level prior to administration.
Dosage amount limit for magnesium threonate
Administering an effective amount of magnesium threonate of less than 1.5 mg/kg body weight/day.
Foodstuff-contained pharmaceutical composition
Providing the pharmaceutical composition contained within a foodstuff.
Oral administration of the pharmaceutical composition
Administering the pharmaceutical composition orally.
Overall, the claim set centers on treating listed solid or cystic cancers by administering magnesium threonate, with dependent claims narrowing treatment to specific physiological magnesium concentration targets (including a 0.75 mM threshold and a ≥10% increase), a dosage limit (<1.5 mg/kg/day), and embodiments using foodstuff containment and oral administration.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?